Xyall Secures €7.6 Million Investment for Automated Tissue Dissection System
Xyall BV has raised €7.6 million from a consortium led by Capricorn Partners to support the global rollout of its Tissector TableTop, an automated tissue dissection system already used in over 15 laboratories in the US. The funding aims to enhance efficiency and accuracy in molecular diagnostics, addressing labor-intensive manual processes and the shortage of laboratory technicians.
Theia Market Signal Identification - AI Assisted
Xyall BV has completed a €7.6 million financing round led by Capricorn Partners through the Capricorn Healthtech Fund II, along with contributions from Sioux Technologies, BOM Brabant Ventures, Health Investment Partners, and private investors. The investment will facilitate the global deployment of Xyall's Tissector TableTop, an automated tissue dissection system currently utilized in more than 15 molecular pathology laboratories across the US.
The Tissector TableTop aims to improve efficiency and accuracy in tissue dissection, a traditionally manual and error-prone task. Introduced in 2023, the system integrates high-resolution imaging and robotics to automate workflows, addressing challenges faced by laboratories amid a technician shortage.
Comments